Centessa Pharmaceuticals plc American Depositary Shares

Monteverde & Associates PC is investigating four merger transactions: LiveRamp Holdings' sale to Publicis Groupe for $38.50/share, NextEra Energy's merger with Dominion Energy, Centessa Pharmaceuticals' acquisition by Eli Lilly for $38.00/share plus contingent value rights, and HCB Financial's merger with Independent Bank Corporation. The firm is...

Nxera Pharma reported strong Q1 2026 results with revenue of JPY 11.3 billion, a significant increase from the prior year, driven by seven R&D milestone events. The company signed a licensing agreement with Santhera for vamorolone in APAC markets, achieved positive Phase 3 results for daridorexant in South Korea, and received milestone payments f...

While Eli Lilly is known for its weight loss drug dominance with Zepbound and Mounjaro, the article highlights the company's underappreciated diversification across oncology, immunology, and neuroscience. With blockbuster drugs like Verzenio ($5.7B sales) and Taltz ($3.6B sales), plus strategic acquisitions in gene therapy and other areas, Eli Li...

Eli Lilly announced a $6.3 billion acquisition of U.K.-based Centessa Pharmaceuticals, a clinical-stage biotech focused on neuroscience. The deal includes up to $1.5 billion in milestone payments tied to Centessa's lead drug candidate cleminorexton for sleep-wake disorders. Despite the large price tag, Lilly's stock reacted positively due to the ...

A major M&A week sees Sysco acquiring Restaurant Depot for $26 billion and McCormick merging with Unilever's food division for $44 billion, while Eli Lilly acquires Centessa Pharmaceuticals for $7.8 billion. The podcast discusses the track record of consumer brand mergers (mostly unsuccessful) and analyzes Whirlpool as a dividend investment amid ...